2023
Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial
Fanucci K, Bai Y, Pelekanou V, Nahleh Z, Shafi S, Burela S, Barlow W, Sharma P, Thompson A, Godwin A, Rimm D, Hortobagyi G, Liu Y, Wang L, Wei W, Pusztai L, Blenman K. Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial. Npj Breast Cancer 2023, 9: 38. PMID: 37179362, PMCID: PMC10182981, DOI: 10.1038/s41523-023-00535-0.Peer-Reviewed Original ResearchPathologic complete responseBreast cancerComplete responseTIL scoreBreast Cancer Pathologic Complete ResponseTumor-infiltrating lymphocyte scoresEvent-free survivalNeoadjuvant chemotherapy trialsLymphocyte measurementsLymphocyte scoreNeoadjuvant chemotherapyChemotherapy trialsMean pretreatmentResidual diseaseTIL quantificationPredictive valuePretreatment samplesResponse discriminationScoresStrong positive correlationPositive correlationAssessment of eligibility criteria in advanced urothelial cancer (aUC) trials based on ASCO-FCR recommendations.
Castro D, Feng M, Prajapati S, Chan E, Lee K, Sehgal I, Patel J, O'Dell A, Zengin Z, Li X, Chehrazi-Raffle A, Dizman N, Tripathi A, Rock A, Liu S, Mercier B, Meza L, Philip E, Dorff T, Pal S. Assessment of eligibility criteria in advanced urothelial cancer (aUC) trials based on ASCO-FCR recommendations. Journal Of Clinical Oncology 2023, 41: 453-453. DOI: 10.1200/jco.2023.41.6_suppl.453.Peer-Reviewed Original ResearchHIV positivityHCV positivityEligibility criteriaCancer trialsExclusion criteriaConcurrent malignancyBrain metastasesCombination therapyExact testClass of therapyTrial eligibility criteriaReal-world populationFisher's exact testRestrictive eligibility criteriaSpecific study populationMultiple cancer typesChemotherapy trialsReal-world practiceInvestigational treatmentStudy populationRadiation therapyClinical OncologyPrognostic toolTherapySignificant association
2022
A Systematic Review of Conversion to Resectability in Unresectable Metastatic Colorectal Cancer Chemotherapy Trials
Chrabaszcz S, Rajeev R, Witmer H, Dhiman A, Klooster B, Gamblin T, Banerjee A, Johnston F, Turaga K. A Systematic Review of Conversion to Resectability in Unresectable Metastatic Colorectal Cancer Chemotherapy Trials. American Journal Of Clinical Oncology 2022, 45: 366-372. PMID: 35838247, DOI: 10.1097/coc.0000000000000921.Peer-Reviewed Original ResearchConceptsMetastatic colorectal cancerUnresectable metastatic colorectal cancerOverall survivalClinical trialsPrimary outcome of OSStudy armsImproved OS of patientsConversion to resectabilitySuperior overall survivalOS of patientsSignificant survival benefitOutcomes of OSMedian survival differenceRandomized clinical trialsHigh response rateDose-effect responseMedian OSImproved OSChemotherapy trialsSurvival benefitExposure of interestPatient cohortSurvival differencesChemotherapeutic agentsColorectal cancerMarital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance)
Lee S, Ma C, Zhang S, Ou FS, Bainter TM, Niedzwiecki D, Saltz LB, Mayer RJ, Whittom R, Hantel A, Benson A, Atienza D, Kindler H, Gross CP, Irwin ML, Meyerhardt JA, Fuchs CS. Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance). The Oncologist 2022, 27: e494-e505. PMID: 35641198, PMCID: PMC9177101, DOI: 10.1093/oncolo/oyab070.Peer-Reviewed Original ResearchConceptsStage III colon cancerRecurrence-free survivalOverall survivalColon cancerCALGB 89803Marital statusAdjuvant chemotherapy trialsColorectal cancer outcomesColon cancer mortalityTime of enrollmentLiving arrangementsChemotherapy trialsSocial support servicesSurvival outcomesCancer mortalityPatient populationCancer outcomesClinical trialsSpouse/partnerWorse outcomesCancer recurrenceNursing homesPatientsSecondary analysisCancerDiet- and Lifestyle‐Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance)
Cheng E, Ou FS, Ma C, Spiegelman D, Zhang S, Zhou X, Bainter TM, Saltz LB, Niedzwiecki D, Mayer RJ, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Giovannucci EL, Van Blarigan EL, Brown JC, Ng K, Gross CP, Meyerhardt JA, Fuchs CS. Diet- and Lifestyle‐Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance). Journal Of Clinical Oncology 2022, 40: 740-751. PMID: 34995084, PMCID: PMC8887946, DOI: 10.1200/jco.21.01784.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantColonic NeoplasmsDietFemaleFollow-Up StudiesHumansLife StyleMaleMiddle AgedModels, StatisticalMulticenter Studies as TopicNeoplasm Recurrence, LocalNomogramsPrognosisRandomized Controlled Trials as TopicRisk FactorsSurvival RateConceptsStage III colon cancerDisease-free survivalLifestyle factorsSelf-reported dietPathologic featuresColon cancerPathologic characteristicsMultivariable Cox proportional hazards regressionCox proportional hazards regressionAdjuvant chemotherapy trialsProportional hazards regressionPredictive survivalChemotherapy trialsDFS eventsOverall survivalSurvival prediction modelHazards regressionSurvival outcomesVisual nomogramLifestyle habitsPatient outcomesCancer recurrenceLifestyle exposuresPatientsCancer
2021
Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance)
Lee S, Zhang S, Ma C, Ou FS, Wolfe EG, Ogino S, Niedzwiecki D, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Gross CP, Irwin ML, Meyerhardt JA, Fuchs CS. Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance). JNCI Cancer Spectrum 2021, 5: pkab034-. PMID: 34104867, PMCID: PMC8178799, DOI: 10.1093/jncics/pkab034.Peer-Reviewed Original ResearchMeSH KeywordsAgedBlack PeopleChemotherapy, AdjuvantColonic NeoplasmsConfidence IntervalsDietDisease-Free SurvivalFemaleHealth Services AccessibilityHumansIncomeLife StyleMaleMiddle AgedMultivariate AnalysisNeoplasm Recurrence, LocalNeoplasm StagingProportional Hazards ModelsProspective StudiesWhite PeopleConceptsAdjusted hazard ratioDisease-free survivalRecurrence-free survivalColon cancer patientsHome zip codeMedian household incomeCALGB 89803Hazard ratioOverall survivalCancer patientsStage III colon cancer patientsStage III colon cancerPatient's home zip codeAdjuvant chemotherapy trialsStudy of patientsColon cancer outcomesHealth care accessChemotherapy trialsStudy enrollmentBlack patientsCancer outcomesLifestyle factorsLowest quartileObservational studyPatients
2016
Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement
Galsky M, Stensland K, Sfakianos J, Mehrazin R, Diefenbach M, Mohamed N, Tsao C, Boffetta P, Wiklund P, Oh W, Mazumdar M, Ferket B. Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement. Journal Of Clinical Oncology 2016, 34: 2627-2635. PMID: 27269939, PMCID: PMC5012691, DOI: 10.1200/jco.2016.67.5033.Peer-Reviewed Original ResearchConceptsCombined-modality therapyLymph node involvementTreated with chemotherapyOverall survivalAdjuvant chemotherapyBladder cancerPreoperative chemotherapyNode involvementDistant metastasisChemotherapy trialsClinical evidence of regional lymph node involvementSurvival of patients treated with chemotherapyTreatment strategiesClinical lymph node involvementEvidence of regional lymph node involvementRegional lymph node involvementNational Cancer Data BasePatients treated with chemotherapyFirst-line chemotherapy trialsNeoadjuvant chemotherapy trialsTreated with cystectomyEffectiveness of treatment strategiesBladder cancer patientsLong-term survivalCystectomy
2013
Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer
Galsky M, Xie W, Nakabayashi M, Ross R, Fennessy F, Tempany C, Choueiri T, Khine K, Kantoff P, Taplin M, Oh W. Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer. Prostate Cancer And Prostatic Diseases 2013, 16: 266-270. PMID: 23712318, PMCID: PMC4026061, DOI: 10.1038/pcan.2013.15.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabChemotherapy, AdjuvantClinical Trials, Phase II as TopicDocetaxelHumansKallikreinsMagnetic Resonance ImagingMaleMiddle AgedNeoadjuvant TherapyNeoplasm Recurrence, LocalProspective StudiesProstatectomyProstate-Specific AntigenProstatic NeoplasmsTaxoidsTreatment OutcomeConceptsHigh-risk localized prostate cancerLocalized prostate cancerBiochemical recurrenceProstate cancerPSA responseNeoadjuvant chemotherapyLikelihood of biochemical recurrenceTreated with neoadjuvant docetaxelAssociated with inferior outcomesEndorectal magnetic resonance imagingResponse to neoadjuvant chemotherapyNeoadjuvant chemotherapy trialsNeoadjuvant systemic therapyMedian Follow-UpMultivariate Cox regressionIntermediate end pointsMagnetic resonance imagingNeoadjuvant trialsNeoadjuvant docetaxelRadical prostatectomyPartial responseSystemic therapyChemotherapy trialsMinor responseErMRIParadoxical significance of endorectal MRI (erMRI) response to neoadjuvant chemotherapy in patients with high-risk localized prostate cancer (HRLPC).
Galsky M, Xie W, Nakabayashi M, Ross R, Fennessy F, Tempany C, Choueiri T, Khine K, Kantoff P, Taplin M, Oh W. Paradoxical significance of endorectal MRI (erMRI) response to neoadjuvant chemotherapy in patients with high-risk localized prostate cancer (HRLPC). Journal Of Clinical Oncology 2013, 31: 23-23. DOI: 10.1200/jco.2013.31.6_suppl.23.Peer-Reviewed Original ResearchHigh-risk localized prostate cancerBiochemical recurrenceRadical prostatectomyPSA responseNeoadjuvant chemotherapyMedian time to biochemical recurrenceLikelihood of biochemical recurrenceTime to biochemical recurrenceAssociated with inferior outcomesResponse to neoadjuvant chemotherapyNeoadjuvant chemotherapy trialsPerioperative systemic therapyLocalized prostate cancerMedian Follow-UpMultivariate Cox regressionEndorectal MRINeoadjuvant trialsNeoadjuvant docetaxelSystemic therapyChemotherapy trialsProstate cancerErMRIClinical parametersInferior outcomesProliferative tumors
2009
Use of pain at baseline and pain progression to predict overall survival (OS) in patients (pts) with docetaxel pretreated metastatic castration-refractory prostate cancer (CRPC): Results from the SPARC trial
Sartor A, Petrylak D, Sternberg C, Witjes F, Halabi S, Berry W, Petrone M, McKearn T, Noursalehi M, George M. Use of pain at baseline and pain progression to predict overall survival (OS) in patients (pts) with docetaxel pretreated metastatic castration-refractory prostate cancer (CRPC): Results from the SPARC trial. Journal Of Clinical Oncology 2009, 27: 5148-5148. DOI: 10.1200/jco.2009.27.15_suppl.5148.Peer-Reviewed Original ResearchCastration-refractory prostate cancerOverall survivalPain progressionBaseline painSPARC trialChemotherapy trialsPPI scoresMetastatic castration-refractory prostate cancerFirst-line chemotherapy trialsMcGill-Melzack Pain QuestionnaireFirst-line docetaxelMedian overall survivalNarcotic analgesic usePre-treated patientsDaily pain intensityImportant prognostic indicatorEffect of painUse of painShortened overall survivalAnalgesic useCRPC patientsMedian survivalPain intensityPain QuestionnairePrognostic indicator
2008
Effect of Molecular Disease Subsets on Disease-Free Survival in Randomized Adjuvant Chemotherapy Trials for Estrogen Receptor–Positive Breast Cancer
Pusztai L, Broglio K, Andre F, Symmans WF, Hess KR, Hortobagyi GN. Effect of Molecular Disease Subsets on Disease-Free Survival in Randomized Adjuvant Chemotherapy Trials for Estrogen Receptor–Positive Breast Cancer. Journal Of Clinical Oncology 2008, 26: 4679-4683. PMID: 18662965, DOI: 10.1200/jco.2008.17.2544.Peer-Reviewed Original ResearchConceptsDisease-free survivalER-positive breast cancerAdjuvant chemotherapy trialsProportion of patientsBreast cancerChemotherapy trialsRS patientsEstrogen receptor-positive breast cancerRandomized adjuvant chemotherapy trialReceptor-positive breast cancerFuture adjuvant studiesProportion of casesTwo-arm clinical trialChemotherapy decreasesMolecular diagnostic testsAdjuvant chemotherapyEndocrine therapyAdjuvant studiesDisease subsetsPositive cancersClinical trialsDFS estimatesRisk groupsEstrogen receptorMolecular subtypesEstrogen Receptor Expression and Efficacy of Docetaxel-Containing Adjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: Results From a Pooled Analysis
Andre F, Broglio K, Roche H, Martin M, Mackey JR, Penault-Llorca F, Hortobagyi GN, Pusztai L. Estrogen Receptor Expression and Efficacy of Docetaxel-Containing Adjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: Results From a Pooled Analysis. Journal Of Clinical Oncology 2008, 26: 2636-2643. PMID: 18509176, DOI: 10.1200/jco.2007.14.9146.Peer-Reviewed Original ResearchConceptsER-negative patientsER-positive patientsRisk of recurrenceDocetaxel therapyER expressionER statusPooled analysisBreast cancerNode-positive breast cancerCox proportional hazards modelAdjuvant chemotherapy trialsDisease-free survivalEfficacy of docetaxelEstrogen receptor expressionPositive breast cancerRisk of deathRandomized clinical trialsProportional hazards modelAdjuvant chemotherapyAdjuvant docetaxelChemotherapy trialsOverall survivalDocetaxel efficacyRandomized trialsClinical variables
2006
Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer
Berry D, Cirrincione C, Henderson I, Citron M, Budman D, Goldstein L, Martino S, Perez E, Muss H, Norton L, Hudis C, Winer E. Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer. Obstetrical & Gynecological Survey 2006, 61: 584-585. DOI: 10.1097/01.ogx.0000234789.05150.7c.Peer-Reviewed Original ResearchER-negative patientsER-positive patientsER-positive tumorsER-negative tumorsNode-positive breast cancerER-negative womenEstrogen receptor statusBreast cancerOverall survivalER statusLymph node-positive breast cancerER-positive breast cancerModern intensive chemotherapyWeak prognostic factorER-positive diseaseLeukemia Group BDisease-free survivalER-negative diseaseOverall survival ratePatterns of riskAdjuvant chemotherapyChemotherapy trialsEndocrine treatmentIntensive chemotherapyRecurrent diseaseA new measurement of residual cancer burden to predict survival after neoadjuvant chemotherapy
Symmans W, Peintinger F, Hatzis C, Kuerer H, Valero V, Hennessy B, Green M, Singletary E, Hortobagyi G, Pusztai L. A new measurement of residual cancer burden to predict survival after neoadjuvant chemotherapy. Journal Of Clinical Oncology 2006, 24: 536-536. DOI: 10.1200/jco.2006.24.18_suppl.536.Peer-Reviewed Original ResearchDistant relapse-free survivalResidual cancer burdenPathologic complete responseResidual diseaseComplete responsePathologic responseAJCC stageCancer burdenMultivariate Cox regression analysisRCB-3AJCC stage IIIHigh-risk patientsCox regression analysisNeoadjuvant chemotherapy trialsRelapse-free survivalDifferent prognostic groupsMedian followNeoadjuvant trialsPaclitaxel scheduleWeekly paclitaxelChemotherapy trialsNeoadjuvant chemotherapyPCR rateStrength of associationSurvival benefit
1993
High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.
Peters W, Ross M, Vredenburgh J, Meisenberg B, Marks L, Winer E, Kurtzberg J, Bast R, Jones R, Shpall E. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. Journal Of Clinical Oncology 1993, 11: 1132-43. PMID: 8501500, DOI: 10.1200/jco.1993.11.6.1132.Peer-Reviewed Original ResearchConceptsAutologous bone marrow supportPrimary breast cancerHigh-risk primary breast cancerBone marrow supportEvent-free survivalBreast cancerMarrow supportLymph nodesActuarial event-free survivalMore axillary lymph nodesHigh-dose consolidationIIIB breast cancerStandard-dose cyclophosphamideTherapy-related mortalityAdjuvant chemotherapy trialsHigh-dose cyclophosphamideAxillary lymph nodesHigh-dose chemotherapyMore lymph nodesAdjuvant chemotherapy treatmentAdjuvant therapyChemotherapy trialsStudy patientsConcurrent cancerStage IIA
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply